PBX3 and colorectal carcinoma: Recent research reported that PBX3 is a novel indicator of epithelial‐mesenchymal transition (EMT) in CRC, and a promising prognostic predictor that may aid in therapeutic decision‐making for patients with CRC.45 These data suggested oncogenic features of PBX3 in CRC, but no previous study had evaluated whether PBX3 methylation in PBL, as a noninvasive test, is a biomarker in CRC to predict prognosis.